Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Medicinus : Jurnal Kedokteran eJournal Kedokteran Indonesia
Harahap, Agnes S.
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Profile of P63 Expression and Epstein-Barr-Encoded RNA (EBER) Distribution in Primary Central Nervous System Lymphoma: A Retrospective Bi-Center Study Kristiani, Erna; Marisca, Stephanie; Suharyani, Sally; Dermawan, Kevin; Widodo, Stephanie T.; Ham, Maria F.; Harahap, Agnes S.; Susanto, Eka; Tjahjadi, Hartono; July, Julius
Medicinus Vol. 14 No. 2 (2025): February
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v14i2.9545

Abstract

Background : Primary central nervous system lymphoma (PCNSL) is a type of lymphoma occurring around 0.5 – 1.2% of all intracranial neoplasms. However, recent epidemiological research shows a threefold increase in the number of cases. The Epstein-Barr virus (EBV) and PCNSL are both associated with the condition of immunosuppression or immunodeficiency, which often found to have a significant relationship with each other. Moreover, the TP63 mutation is associated with a poor prognosis. Methods : This is a descriptive study to assess the expression of TP63 and EBER on PCNSL, and present the characteristics of the disease. The study was conducted on 25 cases from two health centers with the most cases of brain tumors in Indonesia, Siloam Hospital Lippo Village and Cipto Mangunkusumo Hospital (CMH) from 2014 to 2018, the P63 expression and EBER-1 examinations were done by 4 pathologists. A total of 25 patients, 13 (52%) patients were male, ranging from age 30 – 79, with average 57,6 years old, located mostly in the frontal lobe in 8 patients (30.9%). Result : From the research results obtained positive P63 results in 20 cases (80%), while the EBER test was negative for all 25 patients. Further analysis with software SPSS 25 proving that P63 expression is not associated with germinal center B-cell type (GCB) or non-GCB type (p-value 0,87). Neither, P63 have any association with Ki67 with p-value of 1.00. Conclusions : This study concludes that there is a possibility that PCNSL cases in Indonesia are not associated with Epstein-Barr virus infection, but most of the cases will have a poor prognosis as indicated by P63 expression.
Clinical Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated Using R-CHOP Luhuna, Muslimah; Irawan, Cosphiadi; Harahap, Agnes S.; Shatri, Hamzah; Yunir, Em; Sutandyo, Noorwati
eJournal Kedokteran Indonesia Vol. 13 No. 1 (2025): Vol 13, No. 1 - April 2025
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with a fairly high prevalence in Indonesia and a relatively poor prognosis. Addition of rituximab (R) to chemotherapy has led to better efficacy than other regimens in clinical trials. However, data on clinical characteristics and outcomes of patients with DLBCL are scarce. This retrospective cohort study analyzed patients' medical records of DLBCL patients from 2014 to 2021 at dr. Cipto Mangunkusumo National Hospital. Patients’ demographics, clinical characteristics, treatment responses, and 24-month event-free survival (EFS) were assessed using univariate analyses and receiver operating characteristic curves. A total of 100 patients were included, comprising 46% male and 54% female, with the majority (83%) aged <60 years. Complete response (CR) was observed in 44.2% of males and 55.8% of females, while non-complete response (non-CR) occurred in 60% and 40%, respectively. Among patients under 60 years old, CR and non-CR were 92% and 88.4%, respectively. Low and high international prognostic index (IPI) scores accounted for 58.8% and 41.2%, with corresponding CR therapy responses of 27% and 10%, and non-CR therapy responses of 52.9% and 47.1%. The majority of patients were of the non-germinal center B-cell-like (GCB) subtype (81%) compared to GCB (15%), with CR therapy responses of 84.8% and 15.2%, and non-CR therapy responses of 75% and 25%, respectively. The 24-month EFS rate was 68%. The clinical characteristics observed in this study differ from those reported in Western populations, where younger age, female gender, low IPI scores, and non-GCB subtypes were more prevalent. These findings highlight the need for further investigation to understand regional differences in DLBCL better.
Co-Authors Cosphiadi Irawan Dermawan, Kevin E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Em Yunir, Em Julius July Kristiani, Erna Luhuna, Muslimah Maria F. Ham Marisca, Stephanie Noorwati Sutandyo Suharyani, Sally Susanto, Eka Tjahjadi, Hartono Widodo, Stephanie T.